Other research found a promising link between protein intake and GLP-1 secretion
This is one of the most common barriers, and we discuss options at the first visit
Hypoglycemia risk increases when two glucose-lowering agents with insulin-secretagogue properties are co-administered, particularly in patients on concomitant sulfonylureas or insulin [4]
This creates a bimodal distribution, with lots of very happy users and lots of very unhappy users, but relatively few in the middle
The concern historically centered on delayed gastric emptying causing nausea or obstruction, but modern dosing protocols and patient selection have minimized these risks
In addition to generating antibodies, Mojsov needed to devise a chromatographic method to detect GLP-1 (7-37) and separate it from other relevant peptides (Barany, Barany)